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CHAPTER 1: INTRODUCTION 
 
 1.1  EPIDEMIOLOGY OF BREAST CANCER: 
 
  Breast cancer, the most frequently occurring cancer in women, is a major public 
health problem, with 1,384,155 estimated new cases worldwide with nearly 
459,000 related deaths. 
 Breast cancer incidence has been increasing throughout the world (according to 
2012 GLOBOCAN statistics, nearly 1.7 million women were diagnosed with 
breast cancer worldwide with 522,000 related deaths - an increase in breast 
cancer incidence and related mortality by nearly 18 % since 2008). There are 
significant inequalities between rich and poor countries, with the incidence rates 
remaining highest in more developed regions, while mortality rates are much 
higher in less developed countries (the mortality is nearly 17% higher in the less 
developed countries). 
 Breast cancer incidence rates are expected to increase in many less developed 
countries because of longer life expectancy coupled with the adoption of a more 
‘‘westernized’’ lifestyle such as delays in childbearing and less physical activity. 
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1.2  HISTORICAL DEVELOPMENT OF BC TREATMENT  
 
  The surgical management of breast cancer has significantly evolved over the 
years, trending away from radical procedures, and moving towards procedures 
with complete tumor resection while preserving normal parenchyma tissue 
thereby decreasing patient morbidity.  
For most of the twentieth century, Halsted radical mastectomy (or radical 
mastectomy, RM) was the established and standardized operation for cancer of 
the breast in all stages, early and late stage
1
. Halsted radical mastectomy, 
introduced by William Halsted in 1882 at the Roosevelt Hospital in New York 
City, implies the excision of the breast glandular tissue, the associated skin and 
subcutaneous tissue, pectoral muscles (major and minor pectoral muscles) and 
axillary lymph nodes. When mastectomy is coupled with en-bloc resection 
(removal as a whole) of internal mammary nodes, it is often termed an extended 
radical mastectomy.  
  
  In 1948, two reports appeared that were destined to change the management of 
breast cancer. Indeed, they were accepted in 1989 as general principles in the 
management of breast cancer (as a localized disease) 
2
. The first report on 
modified radical mastectomy (MRM) was introduced by D. Patey and W. Dyson 
from Middlesex Hospital in London.  Modified radical mastectomy involves 
the  removal of the entire breast, together with the nipple and the pectoralis 
major fascia, and axillary node dissection is done through the same incision. The 
second report was on Simple Mastectomy and radiotherapy which was 
introduced by R. McWhirter, a radiotherapist of the University of  
Edinburgh (Scotland).  Simple Mastectomy consists of the excision of the entire 
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breast, axillary node dissection (usually through a separate incision), and 5 to 6 
weeks of radiation therapy 
      Halsted mastectomy was performed largely to prevent local or regional 
recurrence. Halsted and many other surgeons believed that all tumors spread by 
direct extension (the theorem of “centrifugal spread”) 3, for example, breast 
cancer can spread to the liver and lungs directly through the layers of the body 
into these organs. The cure of breast cancer was totally in the hands of the 
surgeon; if the tumor could be surrounded and removed, the patient could be 
cured and no recurrence was observed. On the one hand, Halsted mastectomy 
was associated with an important reduction in local and regional recurrence rates 
(Halsted study in 1892 reported 6% (from the prevailing 51-82% at that time) 
and 22% recurrence rates respectively)
 2
 , and on the other hand, despite the use 
of radical mastectomy and consequent loco-regional disease control, there was 
still a high mortality rate.   
  In the first decades of the 20
th
 century, few doctors questioned the doctrine of 
radical surgery, nevertheless, no one dared to confront Halsted mastectomy until 
more than a generation after his death (in 1922). Slowly arguments against 
centrifugal theory began to surface and the theorem subsequently failed (in 
1920). 
   N.E McKinnon (professor of epidemiology at the University of Toronto) said 
that “In most, if not all, lethal breast cancers, the eventual cause of death is 
remote metastasis, and remote metastasis is spread from the primary lesion via 
the blood stream” 4 . In essence, given what he believed about the natural history 
of breast cancer, if the disease had spread, it would have done so long before the 
surgeon’s knife touched the patient, and if this was true, radical mastectomy 
simply made no sense. Also Bernard Fisher (an American scientist and a pioneer 
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in the biology and treatment of BC) believed that, in early stage breast cancer, 
radical treatment would not affect patient survival, and systemic disease or 
micrometastasis determines the outcome of the patient. This theory led to a 
change in local treatment, from Halsted mastectomy to breast conservative 
surgery (BCS) together with adjuvant Radiation Therapy (RT).  
   
 Radiation therapy was introduced by Maria and Pierre Curie in the treatment of 
cancer in 1898 and became widely accepted by 1920. It was introduced first to 
treat inoperable breast cancers, and then as a postoperative supplement to 
mastectomy (and sometimes preoperative to reduce the bulk of large cancers). 
Radiotherapy was later approved for BCS. In 1922, an English surgeon, 
Geoffrey Keynes, began using Local Excision and Radiotherapy to treat STAGE 
I breast cancer. Over seventy percent of his patients had a 5 year survival rate 
and 8% developed local recurrence (this percentage was actually no higher than 
that following radical surgery) 
5
. The benefit of ionizing irradiation after breast 
surgery (Adjuvant RT) is that it destroys occult cancer cells which can be left 
behind, thus reducing local recurrence rates. 
  Nowadays, RT is almost always indicated after Breast Conservation Surgery, 
and may be recommended after Mastectomy (PMRT, Post Mastectomy 
Radiotherapy). Adjuvant RT, in patients who undergo a Mastectomy, is 
indicated for:  T4 tumor or T3 tumor and evidence of node involvement at 
pathologic review, evidence of positive margins showing invasive disease at 
pathologic review, and in the case of ≥ 4 pathologically involved nodes. The 
potential benefits of PMRT in patients with < 4 positive axillary nodes remain 
controversial.  
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  In 1973, Umberto Veronesi (Milan, Italy) began a scientific study comparing 
surgical techniques 
5
 . One technique implied the removal almost one-fourth of 
the breast plus RT. The second technique was Radical Mastectomy. He called 
the first technique, Quadrantectomy. Years later (In 1980), Veronesi 
statistically showed that survival and local recurrence results were equal for both 
forms of treatment. Randomized clinical trials established then the role of Breast 
Conservation Surgery, and concluded that there is no difference in survival of 
patients with early breast cancer whether treated with Halsted’s Mastectomy or 
Quadrantectomy and radiation.  
  By 1991, a National Institutes of Health consensus statement recommended 
Conserving Surgery plus RT as an appropriate alternative primary therapy to 
mastectomy for early stage breast cancer 
6
.
 
  
  The major advantages of Breast Conservation Surgery compared with 
Mastectomy are: superior cosmetic results and reduced psychological  and 
emotional trauma resulting from the procedure.  
 Nowadays, breast conservative surgery includes also more conservative 
techniques than ever, which implies only the resection of the tumor with a 
limited excision of the surrounding tissue. This technique, like almost all 
conservative breast surgery, involves the use of adjuvant RT. However, this 
technique has limits, such as, involved surgical margins (reported in 10-40% of 
cases) with an increase in re-excision surgical rates (reported in 20-30% of 
cases). 
In some patients, mastectomy is still carried out due to: tumor size (relative to 
breast size), tumor multicentricity, inability to achieve negative surgical margins 
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after multiple resections, prior radiation to the chest wall/breast or other 
contraindications to RT, or patient choice. 
  Until recently, surgical management of Breast Cancer (BC) focused on two 
main choices: tumor resection using breast conservation therapy (BCT) and 
mastectomy with optional volume displacement by breast reconstruction. Since 
2003, Oncoplastic Breast Surgery (OBS or OPS) has been introduced. This 
technique combines the skill of resection and reconstruction in one procedure 
7
. 
This can be considered a third option of surgical treatment for breast cancer. It 
has been demonstrated that it is associated with less involved surgical margins 
and re-excision surgical rates and better cosmetic outcomes.   
Moreover, since the last decade of the 20
th
 century, new mastectomy techniques 
have been developed. These techniques are advocated in patients who have to 
undergo complete breast glandular removal, but at the same time the overlying 
skin and the nipple can be conserved. These new techniques of conservative 
mastectomy are the Skin-Sparing Mastectomy and the Nipple-Sparing 
Mastectomy. These two techniques imply, after the entire removal of the gland, 
an immediate reconstruction of the breast. So these approaches offer a one- or 
two-stage procedure for either oncologic and reconstruction surgery, and lead to 
a more natural aesthetic outcome. 
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1.3  DESCRIPTION OF THE MODERN SURGICAL 
TREATMENT FOR BC AND RECONSTRUCTION 
TREATMENT  
 
 
 SKIN/NIPPLE-SPARING MASTECTOMY 
                      
  A- SKIN SPARING MASTECTOMY: 
Skin sparing mastectomy (SSM), a new surgical technique that has advocated in 
the last years of the 20
th
 century is an oncological safe approach for the 
management of patient with breast cancer that minimizes breast deformity and 
improves cosmesis by the preservation of the skin envelope of the breast 
8
. 
 Skin-sparing mastectomy consists in the en-bloc removal of the glandular tissue, 
according to a simple or modified mastectomy, of the Nipple-areola complex, in 
some cases also the adjacent biopsy scars and skin overlying superficial 
tumorswith immediate breast reconstruction. The overlying subcutaneous fat and 
dermis are separated from the glandular tissue and the breast skin envelope and 
infra-mammary fold are preserved. Care must be taken to avoid thin skin flaps 
which could leads to an increase of  skin necrosis.  
The preservation of the natural skin envelope during SSM lead to a more natural 
aesthetic outcome. Furthermore, SSM approaches reduce the need for 
contralateral breast adjustment in order to achieve symmetry. This approach 
offer a single-stage procedure to either oncologic and reconstruction surgery. 
Skin-sparing mastectomy can be performed in the case of: 
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 Ductal carcinoma in situ (DCIS) spread to more than 3cm 
 Multicentric T1 / T2 breast tumors 
 Prophylactic mastectomy 
 In much selected cases in stage III of BC 
 Unfavorable ratio between diameters of tumors and breast 
 
 Skin-sparing mastectomy is contraindicated in:  
 
 Inflammatory carcinoma 
 Locally advanced cancer 
 Intensive smoking (relative contraindication).   
 
 Below 4 types of SSM are indicated. SSM types had been classified according 
to the type of incision used and the amount of skin removed. Factors like tumor 
location and depth and a previous biopsy scars influence the choice of the 
surgical incision 
9
. 
TYPE I SSM, PERIAREOLAR INCISION. It is commonly used in prophylactic 
cases and for non-palpable cancers diagnosed by needle biopsy. In patients with 
small diameter areola, a lateral extension or “tennis racquet incision” is 
sometimes necessary to improve exposure to the axillary tail, or to provide 
access for breast reconstruction. An “elliptical incision” can be fulfill if 
expander/implant reconstruction is performed. The incision should be obliquely 
11 
 
oriented toward the axilla to reduce flattening of the central breast mound. A 
periareolar incisions should have a significantly lower rates of complications 
compared to tennis racquet incisions 
9
 . 
 
Tennis racquet incision 
 
 
Peri-areolar incision 
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TYPE II SSM. It is used when a superficial tumor or previous biopsy is in 
proximity to the areola. In autologous reconstruction, the flap skin can be used to 
fill the defect. In implant-based reconstruction, the skin is closed to facilitate 
breast shape 
9.
       
 
 
TYPE III SSM.  It is used when the superficial tumor or previous incision was 
remote from the areola, usually in the upper quadrants of the breast. Care must 
be taken to ensure the viability of the intervening skin 
9
.    
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TYPE IV SSM . It is used in large, ptotic breasts when a reduction is planned on 
the opposite breast 
9
.  
 
 
Wise pattern incision 
 
A common problem with this technique is the occurrence of native skin flap 
necrosis of the most distal portions of the flap, particularly at the “T” junction.  
To avoid  this complication, it was described a modification of the Wise pattern. 
The area between the vertical limbs of the  T and an additional  2cm outside the 
horizontal limbs are deepithelialized but no resected.   
 
Intraoperative photographs showing Wise pattern incisions with de-
epithelialization of the skin : 
o The area in yellow will be resected as part of the Type IV SSM. This 
excision leaves a rim of dermis along the vertical limbs of the skin excision. 
o The inferior skin flap is elevated down to the inframammary fold.  
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o The deepithelialized inferior skin flap is draped over the tissue expander and 
sutured to the released inferior border of the pectoralis major muscle. Back 
cuts are made to allow inset of the dermal flap.  
o The skin flaps just prior to closure. The deepithelialized vertical limbs serve 
as a buttress.  
 
 
 
Wise pattern incisions 
 
Skin-sparing mastectomy approach could be associated with complications, and 
the most frequent one, is the:  
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Necrosis of the Native Skin Flap 
 The incidence of native skin flap necrosis after SSM, when followed by 
immediate breast reconstruction, was reported to be in 10% to 22% of cases 
9
.  It 
can vary in severity from superficial epidermolysis to full thickness skin loss. 
Complications predisposing factors include, age, breast size, type III and IV 
incisions, preoperative radiation, tobacco smoking, and obesity. 
 
B-NIPPLE- SPARING MASTECTOMY:  
 Nipple-spring mastectomy (NSM), another technique of breast conserving 
surgery advocated in women with early-stage cancer. The goal of the nipple-
sparing mastectomy procedure is to remove all glandular breast tissue in order to 
maximize oncologic therapy, while leaving most of the skin and the nipple-
areola complex (NAC) in place. The surgeon, in this manner, create a natural 
skin envelope, or pocket, that is filled with breast implant. 
Nipple-sparing mastectomy spares the nipple-areolar complex, mandating 
removal of nipple-areola (NA) ducts, and leaving only the epidermis and dermis 
at the NA behind. The recommend thickness of skin flam is between 3-5 mm in 
order to preserve the sub-dermal vessels. When the dissection approaches to 
NAC area, 5 mm thickness is recommended to avoid necrotic complication of 
NAC. Similar to SSM, preservation of the NAC and skin envelope then 
mandates immediate reconstruction.   
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NSM INDICATIONS:  
 
 Extensive or Multicentric Ductal Carcinoma in situ (DCIS) and 
Lobular Carcinoma in situ (LCIS), 
 Multifocal/Multicentric Invasive Ductal or Lobular Carcinomas >1-
2cm distance from the nipple (without skin involvement and/or 
pathologic discharge from the nipple), 
 Prophylactic Mastectomy in patient with BRCA1/2 mutation.  
   
It is generally agreed that involvement of the skin/NAC, inflammatory tumors 
and Paget's disease represent CONTROINDICATIONS FOR NSM.  
An increase risk of NAC involvement is correlated with: tumor location, number 
of positive lymph nodes, lymphovascular invasion, tumor size and distance from 
the NAC (as measured by magnetic resonance imaging).  
Various designs of skin incisions for NSM can be drawn:  
 
Various designs of skin incisions for NSM 
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A) Radial lateral incision. 
B) Peri-areolar with lateral extension. 
C) Hemi-periareolar. 
D) Transareolar. 
E) Circumareolar (periareolar total). 
F) Periareolar with vertical extension. 
G) Circumareolar with vertical extension. 
H) Wise-pattern mastectomy. 
 
 Breast conservation therapy:  
The attempt to preserve the breast without compromising survival in patients 
with early-breast cancer brought up the use of Breast Conserving Therapy 
(BCT). This includes breast conservation surgery (BCS) and breast adjuvant 
radiotherapy. Breast conservation surgery involves (beyond the 
quadrantectomy approach) the completely resection of the tumor with limited 
excision of surrounding breast tissue. The current standard is to accept a rim of 
normal breast tissue (of almost 2mm) all of the way around the tumor as 
evidence of complete excision. 
  Surgical margin is subjected to intraoperative pathologic assessment. If final 
pathologic results for resected tissue show that margins are involved (presence of 
tumor cells), patients undergo additional surgery to avoid local recurrence 
(because the risk of cancer recurrence is increased).  
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Surgical margin 
 
Tumor features can be associated with high risk of positive surgical margins 
such as: 
 Presence of microcalcifications,  
 Mammographic density, 
 Lobular histology, 
 Presence of extensive DCIS component on the core biopsy 
 
Recent improvement in screening approaches (which allow to find most likely a 
smaller mass and still confined cancer to the breast), and neoadjuvant 
chemotherapy, BCS has become a common option and an established alternative 
to mastectomy.  
 Compared with mastectomy, breast conservation therapy allows greater 
preservation of the native breast and aesthetic outcomes with equivalent survival 
rates as has demonstrated by multiple randomized clinical trials.  
Patients with no metastasis (M0), and for whom a primary surgical approach is 
technically not feasible and in patients with operable breast cancer who desire 
breast conservation, could undergo Neoadjuvant therapy. Neoadjuvant therapy 
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primary objectives hear, is to get tumor down-staging and to improve surgical 
outcomes.  
 BCS found indication in:  
   early-stage breast cancer; (TNM staging: T1-T2, N0-N1, M0, or group 
staging: STAGE I, STAGE IIA and IIB).  
Traditional contraindication to perform BCT includes:  
 Large tumor size (>5 cm; although considered relative 
contraindication) 
 Tumor-breast ratio (in case of high ratio) 
 Skin or chest wall involvement 
 Multicentric tumors 
 Anticipated poor cosmetic outcome  
 Controndications to RT  
  
Radiation therapy is almost always advocated after breast conservation surgery 
to eradicate any microscopic residual disease. However, it may not be indicated 
when a patient’s prognosis is favorable or when it is not considered effective. 
 In adjuvant radiotherapy (RT) the entire breast and the contralateral breast get 
radiation, and an extra boost of radiation can be given to the area where the 
cancer was removed, where the risk to relapse is higher than the rest of the gland. 
Adjuvant radiation therapy and boost RT were become a safe option for the 
primary surgical treatment of early breast cancer. Especially boost RT is a 
widely accepted practice in patients at a higher risk of local recurrence, 
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particularly younger patients, and those with close surgical margins
10
. A number 
of different fractionation schedules for breast irradiation have been used. 
Although the most common fractionation schedule has been 50 Gy in 25 
fractions (Traditional schedule). 
 The omission of Adjuvant Radiotherapy is known to reduce local recurrence 
risk and mortality rates after breast conservation surgery, also the success of 
BCT is contingent upon moderate-dose RT in eliminating subclinical foci of 
disease in the homolateral breast, when they exist. Nevertheless, radiotherapy is 
not devoid of side effects. Side effects after RT, include:  
 Increasing breast parenchymal density. 
 Skin thickness and tightening. 
 Breast distortion. 
 Pigmentation changes. 
 Fibrosis. 
 Reduction in breast volume in 10-20% of cases. 
 
  In case of pathological node negative or N1 status, there is no consensus 
amongst European and North-American guidelines for indications of adjuvant 
radiation therapy of the chest wall and axilla in breast conservation therapy. In 
case of N+, all patients should receive Adjuvant Chemotherapy. It should be 
indicated even in patients without N+, but in patients with poor prognostic 
factors based on primary tumor characteristics, such as grading (G; high nuclear 
or histological grade), diameter (cancers > 1cm and cancers <0.5cm with high G) 
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and negative hormone receptors. Nowadays, chemotherapy schedules containing 
TAXANES are standard of care 
 
 
 ONCOPLASTIC BREAST SURGERY (OPS or OBS):  
 A novel surgical approach to the treatment of breast cancer, was developed in 
1990 by German surgeon, Werner Audretsch. 
 Oncoplastic breast surgery has emerged as a new approach for extend breast 
conserving surgery possibilities.  
 Breast anatomic characteristics such as breast size, tumor size, tumor location, 
and tumor-breast ratio, could be limits for the indication of BCS. Besides this, 
the application of BCS is especially limited where a large resection would lead to 
major and definitive deformity of the breast (aesthetic sequel) and free margins 
can not be obtained, provided that aesthetic outcomes remain preserved.  
 One way of resolving this conflict is to use combined approach, which allow 
wide excision of tumor and immediate reconstruction of the resection defects by 
volume displacement using adjacent tissue. Wide excision of tumor helps to 
obtain higher rates of clear surgical margins and lower re-excision rates. 
Immediate reconstruction advocated in OPS is associated with improvement in 
the final appearance of breast by immediately reconstructive surgery without 
compromising cancer care. Furthermore, immediate reconstruction leads to 
greater increase in self-esteem, patient satisfaction and overall survival with, on 
the other hand, decrease in anxiety and depression rates.  
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In addition, after OPS, patients could undergo to a symmetrizing surgery for the 
contralateral breast to improve symmetry, especially in patients with high grade 
of ptosis or with macromastia. Furthermore, because surgery is completed prior 
to radiation (which is almost always indicated), wound-healing problems that 
occur with significant frequency with post-radiation surgery are minimized.  
 When compared with BCS, OPS allows much wider excision and positive 
margins seemed to be much lower in OPS than with BCS. In fact, positive 
margins rates in OPS are ranging from 5% to 18%, comparing with 10%-40% in 
BCS. Instead, when compared with MAS and post-mastectomy reconstruction, 
OPS reduces the burden and morbidity associated with multiple procedures.  
 Close collaboration between the breast surgeon and the plastic surgeon is 
essential in order to obtain the total removal of the tumor and good aesthetic 
results. Plastic surgeon as member of the breast care team, gradually assumes 
more responsibility for reconstruction of any result defect in the breast. Plastic 
surgeon has a crucial role to improve the breast appearance, which is associated 
with better psychosocial well-being, especially in immediate reconstruction.  
 Oncoplastic breast surgery can be indicated in extensive DCIS, invasive lobular 
carcinoma (ILC), multifocal disease, high tumor-breast ratio or in cases of partial 
or poor response to neoadjuvant treatment. Although, it can be indicated in cases 
where BCS would lead to a high risk of re-excision due to margin involvement 
or could cause major esthetic sequel. It also can be implemented within a second 
procedure when positive margins are found after BCS.  
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Surgical methods in case of small or large resection planned:  
1)  When small resection is planned:  
 
o In small breast with/without minimal ptosis  BCT.  
o In Large breast with moderate/sever ptosis  OPS. 
 
2) When large resection is planned:  
 
o In large breast with moderate/sever ptosis OPS. 
o In small breast MAS.   
 
       
 RECONSTRUCTION SURGERIES:  
        
  After a mastectomy the patient can undergo a breast reconstruction surgery. 
Breast reconstruction is achieved through several plastic surgery techniques that 
attempt to restore a breast to near normal shape, appearance and size following 
mastectomy. In addition, a breast lift, breast reduction or breast augmentation 
may be recommended for the opposite breast to improve symmetry of the size 
and position of both breasts. 
 Breast reconstruction, after Mastectomy, is an option which may improve 
psychosocial functioning. However, prospective studies show that in the long-
24 
 
term breast cancer survivorship period (after mastectomy), improvement of the 
psychosocial functioning may be related to the effect of time post-treatment, 
rather than an effect of choice for or against breast reconstruction. Although, 
another prospective study who examined patients one year after their breast 
reconstruction, has indicate that breast reconstruction is not a universal panacea 
for the psychological consequences of mastectomy 
11
. 
Below are indicated several types of the breast reconstruction operations:  
 -    Breast reconstruction can be made in at the same time as Mastectomy is 
done. This approach is called One-stage immediate breast reconstruction. This 
implies the placement of Silicon gel-filled implants into a newly formed pocket, 
surrounded by the minor pectoral muscle on the deeper side, and by the major 
pectoral muscle, together with the muscle’s fascia, the epidermis and dermis on 
the other side. Complete muscle coverage is necessary in order to protect the 
implant from exposure. A special type of absorbable mesh can be used to hold 
the implant in place. This operation can be preferred in women with medium-
small breast.  
The immediate implant placement reduce the need for multiple surgical 
procedures. Anyway, it is not appropriate for all women and it should be use in 
appropriately selected patient. This operation can be preferred, for example, in 
women with medium-small breast.  
Several difficulties and problems had to be faced in performing breast-
reconstruction after Skin-Sparing Mastectomy. SSM enabled the Pectoralis 
Major Muscle to be detached inferiorly where the lower skin flap affords 
coverage to the implant. While expansion is facilitated with the release of the 
muscle inferiorly, pectoral muscle retraction and bottoming out of the implant 
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became problems. A solution might be the suture of the muscle to the fascia, but 
it is not the ideal resolution as frequently it needs more support for the muscle to 
hold in position, and furthermore, the tension might result in disruption while the 
suture cuts through the tissues. 
  A better resolution to these problems is offered by ADM – Acellular Dermal 
Matrices. The ADM reinforces the muscle and provides supplemental tissue 
between it and the infra-mammary fold. It allows the pectoralis muscle to be 
released, expands the space, allows fixation of the infra-mammary fold, and fills 
in the tissue void between the inferior edge of the pectoralis muscle and the 
infra-mammary fold. However, the use of ADM has reported problems  such as: 
seroma, infections, slow vascularisation, disruption, reconstructive failure, 
patient concerns, and costs. But an alternative was found, a long-term resorbable 
synthetic mesh. There were several attempts before finding the right solution. 
Firstly, permanent synthetic mesh, which turned out to be too rigid. Secondly, 
Vicryl, which absorbed too rapidly, and finally, the Matrix Surgical Mesh, which 
offers greater tissue fixation and also functions as a scaffold and facilitates the 
native tissue in-grow.  
 
 -     When the skin flap is not sufficiently stretched to support a full-sized 
implant right away and when adjuvant radiation therapy is indicated, breast 
reconstruction is made by two stages. Two-stages reconstruction implies the 
insertion of an Expander (balloon-like sac) into the newly formed pocket 
(similarly to the previous one) and it gradually filled with physiological saline 
through a tiny valve under the skin in order to stretch the muscle fibre and extend 
the skin above. After approximately six months, the expander, which meanwhile 
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sufficiently straightened the edges of the pocket, is replaced with a permanent 
implant in a second surgery.   
 -    Breast reconstruction with autologous tissues: it is a technique based on the 
removing of autologous tissue flaps from the patient’s:  
o Lower Abdomen area, 
o Or Upper Back, 
o Or Gluteus,  
o Or Inner Thigh.  
  This operation leave 2 surgical sites and scars. The most common types of 
tissue flap reconstruction are from the lower abdomen (called: TRAM 
(transverse rectus abdominis muscle flap or DIEP (deep inferior epigastric 
perforator flap), and from the upper back (called: latissimus dorsi flap). Tissue 
flaps consist in skin, fat, blood vessels, and at least one muscle. Some women, 
have enough tissue in this area to shape the breast, so an implant may not be 
needed.  
 Often, this kind of operations don’t include the remodelling of the other breast 
(to obtain bilateral symmetry) like usually happens during the operations 
previously described. In some cases, implants and autologous tissues may be 
used together for the same reconstruction.  
 -    Breast reconstruction with fat (lipofilling): it consists in the removal of 
adipose tissue from the patient’s own donor area, and its transplant in the 
mammary area. This technique especially helps to effectively correct the volume 
defect after wide excision, for example, after Quadrantectomy.  
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CHAPTER 2: BREAST CANCER CLINICAL 
PATHWAY, LEGISLATIONAL REQUIREMENTS 
AND QUALITY CARE INDICATORS IN THE 
BREAST UNITS  
 
2.1 BREAST CANCER CLINICAL PATHWAY IN THE 
BREAST UNIT 
 
Over the years, the incidence of breast cancer has gradually grown. This increase 
was associated, especially in the last three decades, with a progressive reduction 
in BC relative mortality (by almost one-third). This is due in part to increased 
screening programs and in part to the improved treatments for breast cancer. 
Screening programs are meant to detect cancers at an early stage when the 
chances of successful treatment are higher. They include bilateral mammography 
exam every 2 years in women aged from 50 to 69 years, and in women with 
familial breast cancer with or without proven BRCA mutations,  an annual 
screening with magnetic resonance Imaging (MRI) of the breast, in combination 
with mammography. 
  The Pre-operative diagnosis of BC is based on clinical examination and 
imaging exams. Clinical examination includes Bimanual palpation of the breast 
and loco-regional lymph nodes (Axillary and Supraclavicular). Imaging exams 
include bilateral mammography and ultrasound of the breast, which allow to 
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identify size, site and possible multifocal and/or multicentric disease, and 
ultrasound of the regional lymph nodes. An MRI of the breast, is not routinely 
recommended, apart in cases of: 
 Women with familial BC 
 Breast implants 
 Lobular cancers 
 Suspicion of multifocality/multicentricity (particularly in lobular 
breast cancer)  
 Large discrepancies between conventional imaging and clinical 
examination 
 Before neoadjuvant Chemotherapy 
 When Conventional imaging findings are inconclusive (such as 
CUP Syndrome). 
 
Other clinical assessments include:  
 Complete personal medical history, family history relating to 
breast/ovarian and other cancers 
 Physical examination 
 A full blood count 
 Liver and renal function tests  
 Alkaline phosphatase and calcium levels 
 Menopausal status of the patient 
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 Cardiac function especially in patient who should undergo with 
Anthracyclines and/or Trastuzumab (neo)adjuvant therapy. 
 
The clinical diagnosis should be confirmed by pathological assessment, which 
includes histological examination of the primary tumor (by needle biopsy), and 
cytology examination of the axillary nodes, whether lymph node(s) involvement 
is suspected. The core needle biopsy, must be obtained before any type of 
treatment is initiated. Needle biopsy is mandatory to ensure the clinical diagnosis 
of BC and to assess:  Histological type, Grade, Hormonal receptors expression 
(ER & PgR) and Human Epidermal Growth Factor Receptor 2 (HER-2 or c-
erbB2) expression by Immunohistochemical (IHC) evaluation.  
Once the diagnosis of cancer is made, treatment should be carried out in Breast 
Units and provided by a multidisciplinary team. The Breast Unit (or Center) is 
defined as a specialized department (or departments) where all women have 
access to breast specialists/professionals from a range of disciplines with 
different but complementary skills, knowledge and experience. They work 
together to facilitate treatment planning, to provide the best possible outcome for 
the physical care and psychosocial needs of a patient and to carry out long-term 
follow-up programs. 
  It is demonstrated that a multidisciplinary approach increases the chances of 
survival and quality of life of the patient. 
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The multidisciplinary team includes:  
 Oncological surgeons  
 Plastic and reconstructive surgeons 
 Radiotherapists 
 Medical oncologists 
 Radiologists 
 Pathologists 
 Breast care nurses: In a Breast Center, in addition to the nursing 
staff needed for the management of nursing care in the various services, 
there should be at least two breast care nurses with specific skills in 
counseling and communication and research.   
 Psycho-oncologists: they should allow adequate psychological 
support  
 Fertility specialists: All women diagnosed with breast malignant 
tumor under the age of 38, must be submitted, at the time of diagnosis, to 
counseling at a specialized center for fertility which cooperates with the 
BU. 
 Geneticists: The Breast Unit must have a dedicated medical 
geneticist with experience in the field of hereditary-familial cancers of 
the breast / ovary who accomplish the genetic test during the genetic 
counseling in women with high risk.  
 Physiotherapists: they should be available to evaluate the patient in 
pre-operative and in the immediate post-operative period. They evaluate 
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the occurrence of structural and functional alterations of the homolateral 
arm and shoulder in case of ALND. 
 Afterwards, they should ensure an adequate care of the woman with 
rehabilitative needs for complications and late outcomes. 
 Palliative cares: patients with advanced disease should have a 
specialized service available for palliative care, coordinated with the 
multidisciplinary team to ensure continuity of care.  
 Research services: the Breast Unit must provide training 
opportunities for students and specialists who want to devote themselves 
to breast cancer treatment and organize continuous training courses at 
regional, national and international levels. 
 Voluntary associations: they give information on how to access the 
therapeutic process and the management of side effects. They help the 
patients during treatment, for example, with the services for wigs or, in 
some cases, organizing the transport to the radiotherapy centers or the 
Breast Unit. They create a listening area and organize programs for 
physical and psychological recovery during and after illness. 
Furthermore, they interact with the institutions to ensure the right to 
quality of care, giving patients the opportunity to improve the quality of 
services and to make their voices heard. 
As patient needs may change with time, the composition of the team may also 
change to meet these needs. 
 
The steps that characterize the path of the patients with breast cancer within the 
Breast Unit are: 
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- ►Step 1: Access / CORD.  CORD, is run by trained nursing staff and it is 
accessed in person, by phone or by email. One of the main tasks is to perform a 
kind of triage in order to direct the patient to the next step. 
 
- ►Step 2: More in depth diagnosis through imaging examinations and 
interventional radiology and histopathological diagnosis integrated, if necessary, 
by the biological studies.  
 
- ►Step 3: The first multidisciplinary meeting (MDM). The surgeon or the 
radiologist along with the breast care nurse inform the patient of the diagnosis 
and discuss the treatment plan with her. During the interview, the patient 
receives an indication of the therapeutic strategy as set by the MDM. 
 
- ►Step 4: According to the clinical stage, the path may continue with surgery or 
with medical treatments (in cases in where a neo-adjuvant chemotherapy is 
indicated or in metastatic disease). 
 
- ►Step 5: The definitive histopathologic diagnosis and the second 
multidisciplinary meeting. The patient is informed of the definitive diagnosis and 
on how to continue her path (which in most cases includes drug therapy and 
radiation therapy). 
 
- ►Step 6: The physical and the psychological rehabilitation phase. It starts 
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before the surgical treatment, and can continue during the hospitalization period 
and/or subsequently to it. 
 
- ►Step 7: Follow-up program. Patients who have completed the initial 
treatment, undergo visits and periodic checks to verify an eventual recurrence of 
the disease and eventual treatment’s side effects. 
 
For women with breast cancer, having access to Breast Unit means having 
advanced level structures over all of the:  
1- Italian 
2- And European. 
 The performance of the BU must be evaluated regularly. It also should be a 
continuous upgrading of both staff and equipment. 
  The Breast Units are structured in a network. In order to enhance the 
performance and the resources, networking to smaller hospitals, territorial 
structures, (including hospices) and home care, is required.  
 This Network should be organized according to the Hub and Spoke model: the 
hub ("centre") is the breast centre that offers all the essential requirements to 
treat breast disease; the spokes ("radius") are the second-level centres connected 
to the hub. This system ensures greater presence in the regions, but also an 
equity of treatment for diverse complexity levels. 
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2.2 LEGISLATIVE REQUIREMENTS OF THE BREAST UNIT 
 
  Breast Units were set up for the first time at the beginning of the 21th century 
after the publication of the “Requirements of a Specialist Breast Unit” in 2000 by  
the European Society of Breast Cancer Specialists (Eusoma).  
These same guidelines were published (in the fourth edition of the European 
Guidelines for Quality Assurance in breast cancer screening and diagnosis 
drafted by Eusoma) and adopted by the European Parliament as a basis on which 
to rest the legal regulations (Resolution on Breast Cancer in the European Union 
INI 2002/2279 of 06.05.2003). Recently, the European Parliament has written a 
declaration (No 17/2015 under Rule 136 of Parliament's Rules of Procedure on 
the fight against breast cancer) on the fight against breast cancer in which states 
the importance to implement nationwide mammography screening and 
multidisciplinary specialist breast units by 2016. It was done as called for in the 
European Parliament resolutions of 2003 and 2006 and as required by the 
European Guidelines for Quality Assurance in Breast Cancer Screening and 
Diagnosis to reduce the mortality rates for patients with breast cancer (91495 
women in the EU died from breast cancer in 2012). The commission has also 
recommended that breast cancer patients should have access and be treated 
according to their needs in the Breast Unites. 
  Following the European indications, every nation should ensure the presence of 
a Breast Unit per 250 thousand inhabitants, and the different states must ensure a 
national treatment discipline in accordance with the EUSOMA indications.  
  Furthermore, according to national and international standards, a Breast Unit 
should follow a set of basic and very precise requirements. It must treat more 
than 150 new cases of breast cancer each year, adopt guidelines for the diagnosis 
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and treatment of cancer in all stages and the psychological and physical 
rehabilitation of the patient. Furthermore, it must provide multidisciplinary 
meetings (MMD) with the participation of all members to discuss the treatment 
planning. This includes the assessment of the preoperative diagnosis, the stage, 
the formulation of the therapeutic strategy, the definitive postoperative diagnosis 
and follow-up. The treatment planning, must respect specific indications for: 
surgical, medical, radiation and rehabilitation therapy. The various proposals 
have to be shared with the patient taking in consideration patient’s age, clinical 
features and preferences. 
  Is paramount importance to ensure the observance of the waiting time set in the 
National Plan of Government Lists Hold and the Diagnostic Therapeutic Paths 
for BC. 
 
  In the last 20 years the probability of healing all patients suffering from breast 
cancer has significantly increased. This is associated with greater survival, 
which implies higher rates of follow-up programs. 
There is an important debate in the medical community regard the intensity of 
follow-up programs: minimalist or high intensity. It should be known that, it has 
not been shown an impact on better survival when high intensity follow-ups 
programs were advocated.  
  Patients, who have completed primary treatment, should have regular follow-up 
programs. Regular visits are recommended every 3–4 months in the first 2 years, 
every 6 months from years 3–5 and annually thereafter.  
  The frequency of visits can be adjusted according to the individual patient's 
needs, Patients should be encouraged to report new persistent symptoms 
promptly without waiting for the next scheduled appointment.  
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  It was recommended that the responsibility for follow-up be formally allocated 
to a single physician and that the patient be fully informed of the arrangements 
for follow-up. The follow-up visits represent a good time to share the anxieties 
and fears and to put any question to the professionals. 
 
  The components of the follow-up program and the evidences supporting the 
goals of follow-up  have been up-dated in 2005.  
 
The goals of follow-up are :  
• To detect early local recurrences or contralateral breast cancer. 
•  To evaluate and treat therapy-related complications (such as menopausal 
symptoms, osteoporosis and second cancers). 
• To motivate patients continuing ET (endocrine therapy). 
• To provide psychological support and information in order to enable a return to 
normal life after breast cancer. 
 
Summary of recommendations and indications : 
 Every visit should include a thorough history, eliciting of symptoms 
and a physical examination  
 Annual ipsilateral (after BCT) and/or a contralateral mammography 
with ultrasound are recommended  
 An MRI of the breast may be indicated for young patients, 
especially in cases of dense breast tissue and genetic or familial 
predispositions 
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 Ultrasound can be considered in the follow-up of Lobular Invasive 
Carcinomas 
 Routine blood tests are usually indicated to follow-up patients on 
ET due to the potential side-effects of these drugs, namely in the lipid 
profile. Lipid-metabolism disorders can be the cause of a wide range of 
conditions, with cardiovascular disease being the most significant. 
Because of the high levels of estrogen deprivation caused by aromatase 
inhibitors, the effect of such inhibition on lipid profiles and thus 
cardiovascular disease (is the leading cause of death in postmenopausal 
women in the developed world) become less relevant. It is also important 
to evaluate the tumor markers, such as CEA & CA 15-3 
 For patient on Tamoxifen  therapy an annual gynaecological 
examination, possibly with a transvaginal ultrasound, by an experienced 
gynaecologist is recommended. Tamoxifen use (as adjuvant therapy) is 
associated with an increase risk of endometrial cancer. This risk is 
considered to be a consequence of tamoxifen partial estrogen-agonistic 
effect. 
 Regular bone density evaluation is recommended for patients on 
aromatase inhibitors therapy. Women with a history of breast cancer may 
be at increased risk of osteoporosis because of loss of bone mineral density 
owing to premature ovarian failure from chemotherapy or to aromatase 
inhibitors used as adjuvant therapy. For these reasons, the steering 
committee recommends that osteoporosis be monitored in postmenopausal 
women with breast cancer by a bone mineral density test. 
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 Changes in lifestyle are also recommended such as: regular exercise 
to all suitable patients after treatment of breast cancer and nutritional 
counselling as part of the survivor care for all obese patients. 
 
 
2.3 QUALITY CARE INDICATORS IN THE BREAST UNITS 
 
  In accordance with the EU resolution, a review of literature has been performed 
by an international steering committee in order to identify and define a set of 
indicators for breast cancer healthcare quality assurance. They took into 
consideration national and international guidelines and experts. They focused on 
four key properties of a quality measure. They were:  
 
 Reliability, which means that the observation is highly consistent 
whenever measured. 
 Validity, which means that the indicator is really measuring what it is 
intended to do. 
 Usability, which means the observations have to be easily interpreted. 
 Feasibility, which requires easy data collections during routine clinical 
activities with limited costs. 
 
  These indicators (see Table-1), defined by EUSOMA 
12
, should be routinely 
measured and evaluated in order to confirm that the clinical outcome reaches the 
requested standards. 
  In according to this, the Breast unit of Pisa, one of the three independent 
Teaching Hospitals in Tuscany, is introducing an evaluation system of the 
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performance and quality care to check if it respect the indicators and respond to 
its mission. This is called QT-BREAST. The QT BREAST is the web software 
used for monitoring the quality of diagnosis, treatment and follow-up of BC. It is 
updated with modern practices, and it enables interactive data analysis and 
automatic calculation (evaluation) of the indicators defined by 
SENONETWORK and EUSOMA. 
At a regional level, it is important to ensure parity between different BU(s). The 
use of QT Breast could lead to its common use on the entire regional system 
next. 
There are two groups of indicators: 
- The PROCESS / PATH indicators: they aim in monitoring these indicators is to 
assess the enter path of career and to identify any "weak" steps. 
- The AESTHETIC AND FUNCTIONAL OUTCOME indicators: they aim to 
assess the treatment outcome in terms of aesthetic and functional results. 
  Booth of these groups should be able to measure any "weakness" in the choice 
of the surgical techniques, such as incorrect incision lines, conservative 
interventions without use of Oncoplastic (in cases where these techniques may 
be necessary), removal of excessive tissue to obtain free margins (a phenomenon 
which is observed most frequently at centers with less experience), an excessive 
skin removal or a high-dose of RT even when not necessary on the basis of the 
margins and the type of lesion. 
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Table- 1: Process-path indicators 
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Below are mentioned some quality indicators. 
A) Quality indicators on diagnosis:  
1. Completeness of clinical and imaging diagnostic work-up before the 
operation. 
2. Specificity of diagnostic procedures in order to minimize unnecessary 
operations. 
3. Pre-operative diagnosis - the proportion of women with breast cancer 
(invasive or in situ) who had a preoperative definitive diagnosis. This 
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definitive diagnosis should overcome 80% (as a minimum standard), with 
the target of 90%. 
4. Completeness of prognostic/predictive characterization. This include:  
 Histological type 
 Grading (according to EU guidelines 
 ER   and   PgR  
 HER-2 (or c-erbB2, Human Epidermal Receptor protein-2) 
 Pathological stage (T & N) 
 Size in mm for the invasive component 
 Peritumoral vascular invasion 
 Distance to nearest radial margin  
Estrogen and progesterone receptors (ER and PgR) are prognostic markers 
of outcome, and strong predictive markers of response to endocrine 
therapy and chemotherapy. ER status is strongly influenced by tumor 
grade and histology, for example, all Grade I tumors (well-differentiated 
tumor cells) are more likely ER positive. The presence of hormone 
receptors (ER and PgR) can be tested on the needle core biopsy as well as 
on the resection specimens. ER testing is recommended as a mandatory 
item. The determination of PgR expression is reported along with the ER 
one. PR status, according to what has been demonstrated, is independently 
associated with disease-free and overall survival. In fact, it seems that the 
presence of the Progesterone receptor, without the Estrogen receptor, is 
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associated with worse prognosis, and conversely, the presence of both PgR 
and ER is associated with better prognosis.  
Human Epidermal Growth Factor Receptor 2, is a protein, which is 
expressed at low levels in a variety of normal epithelial cells. 
Amplification of HER-2 gene and concomitant protein overexpression 
were demonstrate in almost 10-20% of primary breast cancers. 
Determination of HER2 status in breast cancer is important, as it has been 
demonstrated that it is a prognostic as well as a predictive marker. In fact 
the presence of HER-2 is associated with a worse prognosis.  
Breast cancers with HER2 alterations are targets for treatment with 
Trastuzumab, a humanized monoclonal antibody. Trastuzumab has shown 
to improve the response and survival rates when added to chemotherapy or 
used as a monotherapy.  
5. Waiting time – The time between the date of the first diagnostic 
examination within the breast unit and the date of surgery/other medical 
treatments should be within 6 weeks. 
6. Use of MRI - The proportion of cancer cases examined pre-operatively by 
MRI. 
7. Genetic counselling availability.  
 
B)  Quality indicators on surgery and loco regional treatments: 
8. Multidisciplinary discussion - The proportion of cases to be discussed by a 
multidisciplinary team.  
9. Appropriate surgical approach in patient with invasive breast cancer: 
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a) The proportion of patients who received a single operation for the 
primary tumor should be higher than 80% (as a minimum standard). 
This means that the proportion of patients who undergo to surgical re-
excision should be lower than 20%.  
b) The proportion of patients with DCIS who received one operation 
(and do not undergo to re-excision surgery secondary to the surgical 
margins involvement) should be higher than 70%.  
c) The proportion of patients with a clinically negative axilla who 
underwent sentinel lymph node biopsy should be higher than 90%. 
d) The proportion of patients who had no involvement of level I 
axillary lymph nodes (after the examination of 10 lymph nodes), 
should overcome 95%. 
10.  Post-operative RT  
a) The proportion of patients with invasive breast cancer and no 
metastasis (M0) who received post-operative radiotherapy after surgical 
resection of the primary tumor and appropriate axillary staging/surgery 
in the framework of BCT, should be more than 90%.  
b) The proportion of patients with involvement of axillary lymph 
nodes ( pN2a) who received post-mastectomy RT, should be higher than 
90% 
11.  Avoidance of overtreatment  
a) The proportion of patients with invasive breast cancer not greater 
than 3 cm (includes also DCIS with T < 3cm) who underwent BCT 
should be higher than 70%. 
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b) The proportion of patients with non-invasive BC with T < 2cm who 
underwent BCT should be higher than 70%.  
c) The proportion of patients with DCIS who do not undergo axillary 
clearance should be higher than 95%. *( axillary involvement in DCIS 
occurs in 1-2% of cases, and it depends on grade and diameter of the 
cancer).  
d) The proportion of patients with invasive BC and pN0 who do not 
undergo axillary clearance should be higher than 80%.  
 
C) Quality indicators on systemic treatment : 
12. Appropriate Hormonotherapy: 
a) the proportion of patients with endocrine sensitive invasive 
carcinoma who received hormonotherapy, should be higher than 80%.  
b) the proportion of patients with ER - and PgR - carcinoma who did 
not receive adjuvant hormonotherapy, should be more than 98%.      
13. Appropriate chemotherapy and other medical therapy- 
a) The proportion of patients with ER- invasive carcinoma (or T > 1cm 
or Node+) who received adjuvant chemotherapy, should be higher than 
80% 
b) The proportion of patients with invasive breast cancer and : T > 
1cm, N positive/negative and positive HER2, treated with chemotherapy 
and who had adjuvant therapy with Trastuzumab, should overcome 
80%. 
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c) The proportion of patients with HER2- breast invasive carcinoma 
who did not received adjuvant therapy with Trastuzumab, should be 
higher than 80%. 
d) The proportion of patients with  HER2+ invasive carcinoma who 
received adjuvant chemotherapy should be higher than 90%. 
e) The proportion of patients with Inflammatory Breast Cancer or with 
ER+ Locally advanced cancer who received neo-adjuvant chemotherapy 
should overcome 90%. 
D) Quality indicators on staging, counselling, follow-up and rehabilitation. 
14. The proportion of women with: 
a)  Stage I BC who do not undergo baseline-staging tests (Ultrasound 
of liver, Chest X-ray and bone scan) should be more than 95%. It is 
shown that the percentage of patients with asymptomatic metastases 
detected with these tests is irrelevant. 
b) Stage III BC who undergo baseline-staging tests (Ultrasound of 
liver, Chest X-ray and bone scan) should be more than 95% 
15. Perform appropriate follow-up – the proportion of asymptomatic patients 
who undergo routine annual mammographic screening and clinical evaluation 
every 6 months in the first 5 years after breast operations should be higher than 
95%. 
16. Avoid inappropriately intensive follow-up : The proportion of 
asymptomatic patients who do not undergo a follow-up protocol that is more 
intensive than local examination (Mammography, Ultrasound and clinical 
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evaluation every 3-4 months in the first 2 years, every 6 months from years 3-5 
and annually thereafter) should be higher than 95%.  
 
Recently, other quality indicators which concern the Aesthetic and  Functional 
outcome after reconstructive surgery have been introduced. These indicators 
evaluate the adequacy of reconstructive surgery (after the oncological surgery) 
on the aesthetic and functional outcomes.   
 
Indicators of functional outcomes : 
The aesthetic outcome must be evaluated in the second year follow-up.  
The indicators include: 
1. Proportion of patients who do not have diastasis or retracted scar after 
BCS and Mastectomy should be more than 80%. 
2. Proportion of patients who do not have skin-discoloration after 
Mastectomy and BCS should be higher than 80% - skin discoloration could 
be evaluated by the definition of its presence or its absence. When it is 
present, it could be darker or lighter than normal skin color. 
3. Proportion of patients who underwent Mastectomy with Immediate 
reconstruction should be higher than 60% - immediate reconstruction should 
be made especially in cases where RT is not indicated and according to the 
patient’s desire. 
4. Proportion of patients who underwent Skin-Sparing Mastectomy and/or 
Nipple-Sparing Mastectomy should be more than 50% - preservation of the 
skin envelope and the infra mammary fold improves breast cosmetics.  
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5. Proportion of patients who underwent Nipple-Sparing Mastectomy should 
be higher than 10% - Nipple Areola complex preservation considerably 
improves breast cosmetic outcome and psychological compliance. It is 
estimated that one-fourth of patients with BC could undergo NSM. 
6. Proportion of patients with permanent implant in immediate reconstruction 
which does not come into direct contact with the subcutaneous mastectomy 
flap should be higher than 95% - direct contact can lead to Exposure, 
Extortion, Dislocation, or Contracture of the implant.  
7. Proportion of patients who underwent reconstruction post mastectomy 
with Human Acellular Dermal Matrix or Synthetic Matrix should be higher 
than 95% - these “ devices” provide a scaffold on the implant.  
8. Proportion of patients who underwent Oncoplastic Breast Surgery should 
be higher than 90%.  
9. Proportion of patients with breast cancer surgery who underwent pre- and 
post-operation photography should be more than 90%. 
10. Proportion of patients who had implant reconstruction failure within 6 
months should be less than 9%. 
 
Indicators of functional outcomes : 
These indicators detect axillar overtreatment.  
1. Proportion of patients who present Lymphedema of the arm after ALND 
should be less than 20% - Lymphedema occurs when protein-rich lymph fluid 
accumulates in the interstitial tissue. Lymphedema leads to arm volume 
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increase and it usually develops gradually over time. Lymphedema is an 
important consideration for clinicians and surgeons because it causes:  
 Increased pain due to the compression of nerves 
  Loss of Function due to swelling and limb changes 
 Depression - Psychological coping as a result of the disfigurement 
and debilitating effect of   lymphedema   
 Lymphedema can occur more frequently in the following cases: 
   -Level III Axillary Lymph Node Dissection 
-After radiation to the lymph node areas after lymph node surgery 
-Extensive cancer in lymph node 
            -Mastectomy rather than BCS 
Patients with Lymphedema should undergo arm circumference measurement in 
specific points; these points are:   
                                                        A-The widest part of the hand 
                                                        C-The wrist 
                                                        E-The elbow                            
                                                        G-The armpit crease 
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2.  Proportion of patients who had Lymphedema after Sentinel Lymph Node 
Biopsy should be less than 5%. 
 
3. Proportion of patients with 10% lower shoulder function in one or more 
postures (such as Flexure, Extension, Abduction, and Adduction) than the 
other shoulder, should be less than 10% : 
 
Limited shoulder function is a good indicator because he can reveal post-
operative complications such as:  
1. Retracted scars. 
2. Unnatural posture 
3. Reduced strength  
4. Radiotherapy. 
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CHAPTER 3:  MATERIALS AND METHODS 
 
 
3.1 AIM OF THE STUDY 
 
The aim of my thesis is to demonstrate the importance of the follow-ups and of 
quality indicators monitoring in order to improve the quality of the breast cancer 
pathway. 
 
3.2 PATIENTS AND METHODS 
 
During 2014, Pisa’s Breast Unit performed 1100 breast operations, 649 of them 
for malignant tumor. Approximately 18 months after the surgery (a range of 12 
to 20 months), all the patients were invited to undergo the follow-up program. 
The data emerging from the follow-up have been included in a specific software 
that can perform real-time monitoring of those indicators. 
I personally took part in the examination of 200 patients 
  In most of the cases the patients were easily reachable and collaborative. 5% of 
them preferred to postpone the appointment, and 10% refused the follow-up for 
fear of potential negative results. It would be interesting to delve deeper the 
emergency of a similar data in the Psycho-oncological field. 
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- A DESCRIPTION OF THE SAMPLE:  
 
  First of all, 63% of the cases were discussed throughout multidisciplinary 
meetings in the preoperative phase, and all of them during postoperative phase. 
 
 
Analysing such data we obtain that: 
 
 4,3% are under 39 years old. 
22,3% 
 are between the ages of 40 and 49. 
30,3% between the ages of 50 and 
59. 27,4% between the ages of 60 
and 69. 13,5% between the ages of 
70 and 79.  And 2,2% between the 
ages of 80 and 89.  
Therefore, we can observe that 
more than half of the patients 
(57,7%) operated on for malignant 
tumor at Pisa’s Breast Unit, during 
2014, were between the ages of 50 
and 69. 
 
 
 
  The familiar anamnesis revealed that 29% of the patients had at least one first-
degree relative positive to breast cancer. 19 patients accomplished the Genetic 
Counselling path in order to verify possible gene mutations. One of them proved 
to be positive to BRCA1, and no one proved to be positive to BRCA2. 
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  In the Personal Medical History, the 48,5% of patients has reported presence of 
mass with the Breast self-examination (BSE), and it had been unveiled by the 
clinical examination in the 68,2% (of all patients). Furthermore, 9% of them had 
a previous Breast Lesion.  
 
49,3% of  the patients had the tumor on the right brest, and the 50,7%  on the left 
one. 
The tumour mass where located as shown below:  
 
 
         left breast         right breast            Total 
   Upper-outer           16,2% 
 
            22,3%             38,5% 
   Outer-central           3,7% 
 
             2,7%             6,4% 
   Lower-outer           4% 
 
             3,7%             7,7% 
   Lower-central           2% 
 
             1,7%             3,7% 
   Lower-inner           4,4% 
 
             2,7%             7,1% 
 Deep Central portion 
      
           1%                1,7% 
               
            2,7% 
   Upper-inner            4,4% 
 
             4,4%             8,8% 
   Upper-central            9,5% 
 
              6,8%             16,3% 
   Areolar region             3,7% 
 
              2,7%             6,4% 
       Diffuse             1,7% 
 
              0,7%             2,4% 
          
         Total 
 
            50,7% 
 
              49,3% 
 
            100%  
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  The pre-operative Histopathology examination made on the needle biopsy of 
the tumour mass, pointed out a definitive diagnosis of malignant breast tumor in 
almost 90% (C5/B5). 
   The post-operative diagnosis has reported in the 86,1% of the cases, Invasive 
Breast Cancer (84% of them was Ductal Carcinoma (or NOS)) , 0,7% was 
Microinvasive Breast Carcinoma, and 0,4%  Non-epithelial malignant breast 
tumor. And in the 11,7% was Carcinoma In situ.  
 
 
  The percentage which concerns the Pathological T stage for the Invasive Breast 
Cancer is reported as below: 
- 2,2% the tumor couldn’t be assessed; 
- 11,3% was carcinoma in situ,(Tis); 
- 8,4% was less than 0,5cm (T1a); 
- 21,9% was more than 0,5cm and less than 1cm (T1b); 
- 36,9% was more than 2cm and less than 3cm (T1c); 
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- 16,8% was more than 2cm and less than 5cm (T2); 
-  0,7% was more than 5cm (T3); 
- And almost 1% has T4.  
 
 
 
  
  Cancer has spread to 1 to 3 axillary lymph node in the 19,7% of cases, and in 
the 59,5% of cases no Lymph Node(s) were involved. 
  The 81% underwent Sentinel Lymph Node Biopsy (SLNB), and the 31,4% 
underwent Axillary Lymph Node Dissection (ALND). 12% of them were 
positive for the SLN and consequently underwent ALND.  
 The surgical operations that were applied to the patients, with the related 
percentage are shown below:  
- 5.3 % underwent Wide Excision (OPS), 
- 62,7% underwent Quadrantectomy (BCS), 
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- 32% underwent Mastectomy, of them: 30% underwent Sample 
Mastectomy, 14,4% to Skin-Redusing Mastectomy, 34,4% to Skin-
Sparing Mastectomy, 21,1% to Nipple-Sparing Mastectomy.  
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The reconstruction surgeries that were applied and the related percentage are 
shown below:  
 
 
 
 
  Metastasis was reported in 2% of cases in the follow-up program after the 
surgical treatment. 50% of them were symptomatic for metastasis. One of them 
was positive to central nervous system metastasis. One had a positive pulmonary 
metastasis. And all of them were positive to skeletal metastasis.  
  Neoadjuvant Chemotherapy was taken in the 9,7%.  And the 90,3% underwent 
at first hand to the surgery treatment. 
 
  10,9% of the patients underwent a second surgery; 63,6% of them underwent 
Mastectomy,  and the 36,4 underwent Wide excision.  
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- The follow-up program: 
 
The day of the follow-up visit, it was used a tracking card with a characteristic 
flower icon for the recall. The patients were called for the medical examination 
in order of the booking date. 
The follow-up visit for this group consisted in two parts: 
o The first part of the assessment, made by the oncologist Surgeon, consisted 
of:  
1. Evaluation of the latest staging tests (blood chemistries test, Tumor 
Markers, Abdominal Ultrasound, and other eventual tests) 
2. Evaluation of the most recent Breast Imaging Exams (Mammography, 
Breast Ultrasound and other eventual tests) 
3. Clinical breast examination with: 
 Evaluation of oncological signs such as skin retraction, contour 
distortion and nodular density (particularly close to the surgical 
scars), which is perceived through palpation 
 Palpation of the axillary and supraclavicular lymph nodes 
 
o The second part of the assessment (assessment of functional and aesthetic 
aspects) was implemented by the plastic surgeon as shown below: 
1. Evaluation of the final cosmetic result through inspection 
2. Measurement of the distance between:  
                                   - The Jugular notch and the Nipple (in both left and right sides). 
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                                   - The Nipple and the inter-mammary point. 
                - The difference, if any existed, in height between the 2 NAC on the 
inter-mammary line. 
3. Evaluation of possible movement limitation of the homolateral 
shoulder, as a post-operative complications, by testing several postures 
(flexure, extension, abduction, and adduction), and revealing eventual 
differences of the movements within the homolateral and the contralateral 
shoulder. 
4. Arm circumference measurement was taken in specific points: the 
widest part of the hand, the wrist, the elbow and the armpit crease, to 
evaluate the presence of lymphedema  
5. Global functional-aesthetic evaluation by means of photographs in 
five projections (frontal, three-quarters (per 2) and profile (per 2)). 
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3.3 RESULTS 
 
As regards process/path indicators it was highlighted that : 
 
Definitive pre-operative diagnosis 
(proportion of C5/B5). 
90.5% (standard 90%) 
Proportion of pre-operative 
histopathology report with type, 
grading, ER and PgR status, stage and 
tumor size for invasive tumor. 
99% (standard 90%) 
Proportion of pre-operative 
histopathology report with type and 
grading for non-invasive tumor. 
98% (standard 90%) 
MRI use for invasive tumor. 58.1% (standard 5%) 
Intraoperative Rx of surgical 
specimen in case of microcalcification 
treated with BCS. 
92.2% (standard 90%) 
Treatment within 30 days from the 
indication for treatment. 
80.6% (standard 90%) 
Indicator not reached 
Treatment within 42 days from the in-
depth diagnostic analysis. 
30% (standard 90%) 
Indicator not reached 
Treatment within 60 days from the 
screening mammogram. 
 
30% (standard 90%)  
Indicator not reached 
A single surgery performing for the 
treatment of invasive carcinoma. 
97.5% (standard 90%) 
A single surgery performing for the 
treatment of non-invasive carcinoma. 
88.3% (standard 90%)  
Indicator almost reached 
At least 10 lymph nodes removed in 
the ALND (excluding sampling). 
98.2% (standard 90%) 
The only sentinel lymph node 
examination in case of pN0  
96.5% (standard 90%) 
No ALND (of any level, including 
sampling) in non-invasive carcinoma. 
98% (standard 90%) 
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Removal of maximum 3 lymph nodes 
in the examination of the axilla with 
sentinel node biopsy. 
 
95.4% (standard 90%) 
BCS performing for  invasive  tumor 
≤ 3cm (including the non-invasive 
component). 
77.8% (standard 90%)  
Indicator not reached 
BCS performing for non-invasive 
tumor ≤ 2cm. 
85.9% (standard 90%) 
Indicator not reached 
RT after the conservative surgery. 96.2% (standard 90%) 
 
RT within 12 weeks after surgery in 
cases where adjuvant CT was not 
performed. 
40% (standard 90%)  
Indicator not reached 
 
Adjuvant endocrine therapy for 
endocrine-sensitive invasive cancer. 
96.6% (standard 90%) 
 
Adjuvant chemotherapy in ER- 
invasive tumor (T>1 cm o N+). 
91% (standard 90%)  
Adjuvant therapy with Trastuzumab in  
N+ or N- T>1cm HER2+ invasive 
tumor. 
100% (standard 90%)  
Neoadjuvant chemotherapy in cases of 
inflammatory carcinoma 
98% (standard 90%) 
  
 
As regards the aesthetic and functional indicators , it is highlighted that: 
 
Proportion of BCS which does not 
report scar’s retraction and diastases 
85% (standard 80%)  
Proportion of Mastectomy which does 
not report scar’s retraction and 
diastases. 
88.2% (standard 80%) 
Proportion of BCS which does not 
report skin discolorations.  
83.3% (standard 80%) 
Proportion of Mastectomy which does 85.8% (standard 80%) 
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not report skin discolorations. 
Proportion of immediate 
reconstruction after Mastectomy 
73.5% (standard 60%) 
Proportion of SSM and NSM among 
all the Mastectomies. 
67.4% (standard 50%) 
Proportion of NSM among 
mastectomies with an immediate 
reconstruction. 
28.2% (standard 10%) 
Proportion of mastectomies with an 
immediate reconstruction with 
implants not in contact with the 
dermis. 
 
100% (standard 95%) 
Proportion of lesions discussed in the 
MMD (benign excluded ).  
98% (standard 90%) 
Proportion of prosthetic implants not 
removed on mastectomies with 
immediate reconstruction. 
 
96.3% (standard 91%) 
Absence of lymphedema of the 
ipsilateral arm after ALND. 
 
90% (standard 80%) 
Absence of lymphedema of the 
ipsilateral arm after SLNB. 
96.9% (standard 95%) 
Absence of shoulder movement 
limitations. 
 
97% (standard 90%) 
Absence of dystopia of the NAC. 
 
70.5% (standard 80%) Indicator 
not reached 
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CHAPTER 4: DISCUSSION 
 
   
 Breast cancer is an important cause of morbidity and mortality among women 
and, in recent years, incidence of this disease has increased progressively 
worldwide 
  The incidence and mortality rates increase along with age, with a peak 
incidence around 60 years old. By the end of the eighties, there was a moderate 
but continuous reducing in mortality rates. This, due to therapeutic advances and 
greater diagnosis in the early stage of BC, due to .in large part, the increasing use 
of screening programs. 
  The increase in incidence and simultaneous reduction in mortality is associated 
with an increase in the prevalence (women living after diagnosis of BC). The 
wide population of patients treated for BC, requires an extended monitoring over 
time. 
Therefore, apart from the obvious need to set an adequate and correct 
oncological treatment, it is of absolute importance to create for the patients an 
organized and systematic program of follow-up. 
  Numerous findings from the international literature have in fact demonstrated 
that the prognosis of patients suffering from breast cancer is affected 
significantly by the possibility to contact and rely on a specialized center for the 
treatment of this disease, in order to have a multidisciplinary team that can 
individualize the treatments. An essential element in managing these patients is 
the presence of all the professionals needed to offer the best opportunities for 
care and the proper attention to the psychological and social needs with a 
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multidisciplinary approach, through which, every expert, help to accompany the 
patient in this difficult path. 
In order to facilitate a uniform collection among the various Breast Units and for 
allowing their systematic processing, a specific software known as QT BREAST 
has been developed. 
  The QT BREAST, updated with respect to the most recent guidelines, enables 
interactive data analysis and automatic calculation of the indicators. It is an 
instrument that controls adhesion to EUSOMA indicators by the various breast 
centers and a system that monitors the quality of the interventions. It also enables 
each center to be able to act quickly on any identified 'weaknesses' in order to 
guarantee a standard quality of care. 
Finally, it also represents an important upgrade tool for  the recommendations 
and a significant starting point for research projects in the field of breast cancer 
treatment. 
In fact, concerning those indicators for which the breast center does not reach the 
minimum required standards, the multidisciplinary team should agree on 
appropriate corrective actions. 
 The Breast Care Unit of the University Hospital of Pisa adopted the use of QT 
BREAST in July 2015 by introducing data on patients operated in the previous 
year into its software 
 
Analyzing the findings from the evaluation of the path / process indicators at the 
Breast Unit of Pisa I observed: 
 
- A correct and thorough pre-operative cytological and histological definitive 
diagnosis for malignant tumor (C5/B5) with more than 90% of cases (90,5). 
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- An accurate and complete pre-operative histopathology report with type, 
grading, ER and PgR status, stage and tumor size registered in 99% of the 
cases. 
 
- A wide pre-operative Magnetic Resonance Imaging (MRI) use (58,1%, instead 
of 5%). It should be remembered that the Radiology School in Pisa was one of 
the first to introduce the use of MRI in the diagnostic clinical approach for breast 
disease. 
  Nowadays, there is no parity on MRI use in the different breast centers. Pisa 
Breast Unit falls within the group that most frequently adopts this imaging test 
with the following  indications: 
 
o In the preoperative study of dense breasts, when they are difficult to 
evaluate with a mammography and ultrasound in order to exclude 
multicentric forms, and a MRI is associated  with increased diagnostic 
accuracy. 
o To evaluate the response to primary systemic therapy. 
o To search for occult carcinoma (CUP Syndrome). 
o In familial breast cancer with or without BRCA mutations. 
o Clinical-instrumental discrepancy (palpable coarse lesions against 
minimum mammographic findings). 
 
- Proper use of Rx of the surgical specimen in non-palpable lesions (92,2%). 
- Time between the date of initial breast cancer diagnosis and the date of surgery 
in the Breast Unit of Pisa is almost 35-40 days, while EUSOMA and Regional 
Resolutions and Recommendations provide for a maximum of 30 days. This 
moderate delay is caused, despite the best efforts of the medical and nursing 
66 
 
staff, by the fact that Pisa’s Breast Unit is one of the most important centers in 
Italy for breast care so there is an influx and a high volume of patients also from 
other Regions.  
 
- In relation to proper pre-operative planning by a multidisciplinary team, single 
surgery was advocated in the 97,5% for invasive cancer, and above the threshold 
for non-invasive cancer (88,3%). 
- Absolute appropriateness for axillary treatment (SLN Biopsy and/or ALND 
where indicated). 
- More Mastectomies were done than Conservative Surgeries (especially 
Quadrantectomies).  
 This datum is affected by: 
1. An excessive rigidity of the indicators. Indeed, it must be taken into 
consideration that: the tumor/breast ratio, the multicentricity of the disease, 
local relapse after (previous) surgical treatments, and the preferences of the 
patients are conditions that require mastectomies. 
2. The specific features of the Center. (the increased use of mastectomy in 
this Center is associated also to the high volume of young patients as well 
as to the increased use of the genetic testing with, consequently,  
prophylactic mastectomies ). 
 
- The use of Radiation therapy (RT) after BCS: The indications for RT are 
followed (96,2%) with the exception that the BU starts treatment after 16 weeks 
instead of 12.  
 
- Chemotherapy follows the best standards for: (T >1cm or N+) ER- Invasive 
tumor and for inflammatory breast cancer (91% and 98% respectively). 
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  It should be emphasized that the previous indicators (Indicators of process/ 
path) have had a broad consensus in the literature.   
 
  The detection of the aesthetic/functional outcomes is a recent approach, and 
still being debated and considered experimental. The aesthetic and functional 
outcome is related to surgical expertise, correctness and completeness of 
treatment planning and it is also related to the response of the tissue, which is 
unpredictable. 
 
  From the examination of the aesthetic / functional outcome indicators emerges: 
- An acceptable percentage of scar retraction and diastases after conservative 
surgery (15%) and mastectomy (11.8%). 
- Skin discolorations rates were higher in BCS (16,7%) than Mastectomy 
(14,2%). This because Adjuvant RT is almost always performed after BCS, 
while is not always indicated in mastectomies. Discoloration of the surgical scars 
reported a very lower incidence where adjuvant radiotherapy was not performed.  
- An elevated use of immediate reconstruction after mastectomy (73.5%).   
I would like to emphasize that I have personally witnessed that the general rule 
after mastectomy in Pisa BU is to propose breast reconstruction. This requires 
more time spent between the surgeons (oncological and plastic surgeons) and the 
patients to decide the best type of reconstruction.  Breast reconstruction may be 
performed immediately after Mastectomy, or in two separate interventions. In 
fact, BU of Pisa do not resort to reconstruction in only two cases:    
1. In case of locally advanced and/or inflamed breast cancer where RT post-
operative is indicated. 
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2. In the case of elderly patients and/or patients with comorbidity that 
contraindicates a reconstruction and/or patients who choose not to have 
reconstruction.  
- In regard to the proportion of cases discussed by multidisciplinary team, I have 
personally found that, in post-operations, all the cases of Malignant Breast 
Tumor are discussed by a multidisciplinary team (MDT). This also occurs with a 
large proportion of preoperative cases (recommended by the international 
guidelines). 
- The need to remove the prosthetic implant (due to infectious complications or 
to necrosis of the flap) is considered a sporadic event (3.7%). 
- The arm’s lymphedema rates after each of, ALND and SLNB are absolutely 
acceptable as are the shoulder articular limitation rates.   
- Dislocation of the Nipple-Areola Complex (NAC) represents a frequent 
complication, and it relies on the increased use of Nipple Sparing Mastectomy in 
the BU of Pisa. During my internship, I spoke with surgeons and plastic 
surgeons, and I came to realize that, while preserving the NAC in order to 
optimize aesthetic shape of the breast is preferable, it is technically difficult to 
maintain the nipple centered and at the same level of the contralateral breast. 
Developments in surgical techniques may lead to an improvement in this area. In 
any case, the dislocation rates recorded in The BU of Pisa (29.5%) are absolutely 
in line with the data in the literature. 
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CHAPTER 5: CONCLUSIONS  
 
 It is of foundamental importance to monitor the quality of care in 
multidisciplinary oncological pathways.  Breast cancer care, patient’s quality of 
life and survival can be maximized with a multidisciplinary team of specialists 
which include oncological surgeons, plastic and reconstructive surgeons, 
radiotherapists, medical oncologists, pathologists, radiologists and breast care 
nurses. 
It is extremely important to monitor the outcomes in yearly follow-ups  because 
breast cancer has a high incidence  and, fortunately, a low mortality rate, 
meaning a high prevalence rate.  This implies that  follow-up programs must be 
carried out to evaluate treatment side effects such as scar’s retractions and 
diastases, skin discolorations, dystopia of the NAC, inadequacy of the breast 
volume and shape, lymphedema, altered arm sensitivity, limited shoulder 
movements and to evaluate local recurrence or metastasis. 
There is a relevant need for quality indicators and monitoring systems for the 
quality of diagnosis, therapy, reconstruction and rehabilitation. The measurement 
of these indicators is effective under many aspects;  Reliability (which means 
that the observation is highly consistent whenever measured), Validity (which 
means that the indicator is really measuring what it is intended to do), Usability 
(which means the observations have to be easily interpreted), Feasibility (which 
requires easy data collections during routine clinical activities with limited 
costs), and Challenge (which means increasing the average quality of Breast 
Units).  
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As of today, both quality indicators as well as monitoring processes are still in an 
experimental phase.  However, they are potential means to improve the quality 
of care in all breast units. 
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